Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kobayashi Kako Recalls 12 More APIs after On-Site Inspections
December 25, 2020
- Daiichi Sankyo Espha Stops Supply of 3 APIs after Kobayashi Kako Mix-up
December 25, 2020
- Mitsubishi Tanabe to Revise Company Rules for Common-Law Marriages, Same-Sex Relationships
December 25, 2020
- 49 APIs Listed in 2020, 10 Billion-Plus Yen Peak Sales Projected for 17: Jiho Tally
December 24, 2020
- Kyowa Kirin Adjusts Shipment of Depakene after Kobayashi Kako Drug Mix-Up
December 24, 2020
- Sales Rep Promotions Down Both in GP, HP Markets in October: Intage
December 24, 2020
- Sosei, Captor to Collaborate on Targeted GPCR Degradation
December 23, 2020
- Axcelead Looks to Unearth New Drugs from Takeda’s Legacy Assets, 5-Plus Collaborations Ongoing
December 23, 2020
- Maruho Taps Atsushi Sugita as New President
December 23, 2020
- JCR Files Hunter Syndrome Drug in Brazil
December 23, 2020
- Takeda, PeptiDream to Develop Peptide Drug Conjugates for Neuromuscular Diseases
December 23, 2020
- Nichi-Iko Stops Supply of Clinoril Due to Dissolution Issue
December 23, 2020
- Meiji, Again, Halts Supply of Kobayashi Kako-Made Drugs after On-Site Inspections
December 23, 2020
- Sosei, GSK Seal Global Deal Targeting GI Disorders
December 22, 2020
- Xospata Fails to Hit Goal in PIII Combo Trial: Astellas
December 22, 2020
- FDA Approves Iclusig for Resistant/Intolerant CML
December 22, 2020
- Takeda Offloads 5 Non-Core Assets in China for US$322 Million
December 22, 2020
- Takeda Slated to Launch Japan PI/II for Moderna Shot in January
December 22, 2020
- Mirogabalin Hits Primary Endpoint in PIII for Central Neuropathic Pain After Spinal Cord Injury: Daiichi Sankyo
December 21, 2020
- Eisai's New Manufacturing Site Completed, Set to Begin Lenvima Production in FY2021
December 21, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…